Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose bortezomib + melphalan + prednisone in multiple myeloma
2013-002157-29Phase 3Completed
- Sponsor
- Ernesto Pérez Persona
- Start
- Aug 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Ernesto Pérez Persona. Primary endpoints: progression-free survival at 18 months and overall progression-free survival. Started Aug 2014; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-002157-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002157-29.